Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-03-2008

Medical consequences of acromegaly: What are the effects of biochemical control?

Authors: Annamaria Colao, Renata S. Auriemma, Rosario Pivonello, Mariano Galdiero, Gaetano Lombardi

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2008

Abstract

This chapter discusses the effects of biochemical control of acromegaly on cardiovascular diseases, metabolic complications, respiratory abnormalities, malignancies and bone alterations. Acromegaly is associated with increased morbidity and mortality for cardiovascular and respiratory complications, whereas neoplasms seem to be a minor cause of increased risk of death. Other associated diseases are osteoarthritis, carpal tunnel syndrome, fatigue, visual abnormalities and reproductive disorders. Acromegaly results in premature death because of prolonged elevation of GH an IGF-I levels, and a strong biochemical control improves well-being and restores life expectancy to normal. The main goals of medical treatment of acromegaly include normalization of biochemical markers of disease activity, improvement in signs and symptoms of the disease, removal or reduction of tumor mass and preservation of pituitary function.

Melmed S. Acromegaly. N Engl J Med. 2006;355:2558–73.PubMedCrossRef

Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526–9.PubMedCrossRef

Petrossians P, Borges-Martin L, Espinoza C, Daly A, Betea D, Valdes-Socin H, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152:61–6.PubMedCrossRef

Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, et al. Partila surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91(1):85–92.PubMedCrossRef

Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insuline-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006;91:1239–45.PubMedCrossRef

Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800–4.PubMedCrossRef

Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61:209–15.CrossRef

Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: long-term (up to nine years) prospective study af its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397–403.PubMedCrossRef

Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, et al. Predictors of tumor shrinkage ater primari therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91(6):2112–8.PubMedCrossRef

10.

Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, et al. The novel somatostatin ligand (SOM 230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab. 2004;89(6):3027–32.PubMedCrossRef

11.

van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638–45.PubMedCrossRef

12.

Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonet V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor anatgonist pegvisomant. N Engl J Med. 2000;342:1171–7.PubMedCrossRef

13.

Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154:467–77.PubMedCrossRef

14.

Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90(10):5627–31.PubMedCrossRef

15.

Feenstra J, de Herder WW, ten Have SM, van der Beld AW, Feelders RA, Janssen JA, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644–6.PubMedCrossRef

16.

Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54:137–54.CrossRef

17.

Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276–83.PubMedCrossRef

18.

Hejtmancik MR, Bradfield JY, Herrmann GR. Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med. 1951;34:1445–56.PubMed

19.

Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100:41–52.PubMedCrossRef

20.

Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777–81.PubMedCrossRef

21.

Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24:272–7.PubMedCrossRef

22.

Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13:51–6.PubMed

23.

Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle. Br Heart J. 1989;62:185–94.PubMedCrossRef

24.

Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. J Clin Endocrinol Metab 2003;88:3196–201.PubMedCrossRef

25.

Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf). 2001;54:515–24.CrossRef

26.

Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitami S, Kouhara H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf). 2001;54:791–6.CrossRef

27.

Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, Di Somma C, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87:3174–9.PubMedCrossRef

28.

Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf). 2001;55:307–13.CrossRef

29.

Colao A, Cuocolo A, Marzullo P, Nicolai M, Ferone D, Della Morte AM, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab. 2001;86:1551–7.PubMedCrossRef

30.

Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest. 1991;14:17–23.PubMed

31.

Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 1992;117:719–26.PubMed

32.

Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 1993;77:790–3.PubMedCrossRef

33.

Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, et al. Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients. J Clin Endocrinol Metab. 1999;4:527–32.CrossRef

34.

Manelli F, Desenzani P, Boni E, Bulgari G, Negrini F, Romanelli G, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999;2:205–10.PubMedCrossRef

35.

Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;86:3132–40.CrossRef

36.

Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab. 1999;84:17–23.PubMedCrossRef

37.

Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol (Oxf). 2003;58:169–76.CrossRef

38.

Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S, Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a prospective multicenter study. J Endocrinol Invest. 2002;25:971–6.PubMed

39.

Colao A, Ferone D, Cappabianca P, Del Basso De Caro ML, Marzullo P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308–14.PubMedCrossRef

40.

Herrington AM, George KW, Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy 1998;18:413–6.PubMed

41.

Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007;92(2):476–82.PubMedCrossRef

42.

Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res. 2001;34:1429–33.PubMedCrossRef

43.

Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca. 2000;27:27–31.PubMedCrossRef

44.

Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52:549–55.CrossRef

45.

Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972–8.PubMedCrossRef

46.

Nikkila EA, Pelkonen R. Serum lipids in acromegaly. Metabolism 1975;24:829–38.PubMedCrossRef

47.

Wildbrett J, Hanefeld M, Fucker K, Pinzer T, Bergmann S, Siegert G, et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes. 1997;105:331–5.PubMedCrossRef

48.

Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gomez-Coronado D, Balsa Barro JA, Varela C, et al. Effects of normalization of GH hypersecretion on lipoprotein (a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf). 2000;53(3):313–9.CrossRef

49.

Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, et al. Evaluation of insuline resistance in acromegalic patients bifore and after treatment with somatostatin analogues. J Endocrinol Invest. 2003;26(6):533–8.PubMed

50.

Ferone D, Colao A, van der Lely A-J, Lamberts SWJ. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging. 2000;17:81–92.PubMedCrossRef

51.

Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86:2779–86.PubMedCrossRef

52.

Colao A, Pivonello R, Auriemma RS, Galdiero G, Savastano S, et al. Beneficial effects of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157:1–10.CrossRef

53.

Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003;149:521–7.PubMedCrossRef

54.

Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91.PubMedCrossRef

55.

Linberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab. 2007;92(5):1724–28.CrossRef

56.

Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000;151:551–7.PubMedCrossRef

57.

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev. 2004;25(1):102–52.PubMedCrossRef

58.

Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692–9.PubMedCrossRef

59.

Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab. 2001;86:2929–34.PubMedCrossRef

60.

Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med. 1991;115:527–32.PubMed

61.

Luboshitzky R, Barzilai D. Hypoxemia and pulmonary function in acromegaly. Am Rev Respir Dis. 1980;121:471–5.PubMed

62.

Donnelly PM, Grunstein RR, Peat JK, Woolcock AJ, Bye PT. Large lungs and growth hormone: an increased alveolar number? Eur Respir J. 1995;8:938–47.PubMed

63.

Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers RD, Winkelmann W, et al. Sleep apnoea in treated acromegaly: relaite frequency and predisposing factors. Clin Endocrinol (Oxf). 1996;45:563–9.CrossRef

64.

Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, et al. Rapid improvement of sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201-995. Lancet. 1986;1:1270–1.PubMedCrossRef

65.

Ip MSM, Tan KCB, Peh WCG, Lam KSL. Effects of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf). 2001;55:477–83.CrossRef

66.

Thomas SG, Woodhouse LJ, Pagura SM, Ezzat S. Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol (Oxf). 2002;56:351–8.CrossRef

67.

Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998;83:2730–4.PubMedCrossRef

68.

Renehan AG, Bhaskar P, Painter JE, O’Dwyer ST, Haboubi N, Varma J, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85:3417–24.PubMedCrossRef

69.

Cats A, Dullaart RP, Kleibeuker JH, Kuipers F, Sluiter WT, Hardonk MJ, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56:523–6.PubMed

70.

Ma J, Pollack MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–5.PubMedCrossRef

71.

Colao A, Balzano A, Ferone D, Panza N, Grande G, Marzullo P, et al. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) 1997;47:23–8.CrossRef

72.

Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664–9.PubMedCrossRef

73.

Burt RW, Samowitz WS. The adenomatous polyp and the hereditary polyposis syndromes. Gastroenterol Clin North Am. 1988;17:657–78.PubMed

74.

Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251–70.PubMedCrossRef

75.

Bogazzi F, Ultimieri F, Raggi F, Costa A, Gasperi M, Cecconi E, et al. Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab. 2002;87:2403–6.PubMedCrossRef

76.

Colao A, Pivonello R, Auriemma RS, Galdiero M, Ferone D, Minuto F, et al. The association of fasting insulin concentrations and colonic neoplasm in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab. 2007;92:3854–60.PubMedCrossRef

77.

78.

Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85:3218–21.PubMedCrossRef

79.

Cheung NW, Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf). 1997;46:545–9.CrossRef

80.

Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Acromegaly Study Group of the Italian Society of Endocrinology, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25:240–5.PubMed

81.

Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol. 2005;63:161–7.CrossRef

82.

Balkany C, Cushing GW. An association between acromegaly and thyroid carcinoma. Thyroid. 1995;5:47–50.PubMedCrossRef

83.

Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary 2002;5(1):21–5.PubMedCrossRef

84.

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced stage prostate cancer. J Natl Cancer Inst. 2002;94:1099–106.PubMed

85.

Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marino V, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab. 1998;83:775–9.PubMedCrossRef

86.

Colao A, Marzullo P, Spiezia S, Ferone D, Giaccio A, Cerbone G, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab. 1999;84:1986–91.PubMedCrossRef

87.

Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34.PubMedCrossRef

88.

Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, et al. Effect of two years of growth hormone/insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab. 2000;85:3754–61.PubMedCrossRef

89.

Detenbeck L, Tressler H, O’Duffy J, Randall RV. Peripheral joint manifestations of acromegaly. Clin Orthoped. 1973;91:119–27.CrossRef

90.

Lieberman SA, Bjorkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab North Am. 1992;21:615–31.

91.

Scarpa R, De Brasi D, Pivonello R, Marzullo P, Manguso F, Sodano A, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 2004;89:598–603.PubMedCrossRef

92.

Kameyama S, Tanaka R, Hasegawa A, Tamura T, Kuroki M. Subclinical carpal tunnel syndrome in acromegaly. Neurol Med Chir (Tokyo). 1993;33:547–51.

93.

Jenkins PJ, Sohaib SA, Akker S, Phillips RR, Spillane K, Wass JA, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med. 2000;133:197–201.PubMed

94.

Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51(5):611–8.CrossRef

95.

Colao A, Cannavò, S, Marzullo P, Pivonello R, Squadrito S, Vallone G, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148:31–8.PubMedCrossRef

Title: Medical consequences of acromegaly: What are the effects of biochemical control?
Authors: Annamaria Colao
Renata S. Auriemma
Rosario Pivonello
Mariano Galdiero
Gaetano Lombardi
Publication date: 01-03-2008
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2008
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-007-9062-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Does acromegaly enhance mortality?

Radiation therapy in acromegaly

Surgery for acromegaly: Evolution of the techniques and outcomes

Medical therapy: Options and uses

Acromegaly: Re-thinking the cancer risk

Current diagnosis of acromegaly

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials